{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T21:07:43Z","timestamp":1784408863267,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,23]]},"DOI":"10.7759\/cureus.84688","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T19:31:38Z","timestamp":1748028698000},"source":"Crossref","is-referenced-by-count":1,"title":["Pseudocellulitis Due to Antineoplastic Therapy: A Case of Atypical Presentation and Recent Developments"],"prefix":"10.7759","author":[{"given":"Shiva","family":"Salmasi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Gafarzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruba","family":"Alchaikh Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantin","family":"Dasanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-3083.2002.00485.x","article-title":"Gemcitabine-induced erysipeloid skin lesions in a patient with malignant mesothelioma","volume":"16","author":"Kuku I","year":"2002","unstructured":"Kuku I, Kaya E, Sevinc A, Aydogdu I. Gemcitabine-induced erysipeloid skin lesions in a patient with malignant mesothelioma. J Eur Acad Dermatol Venereol. 2002, 16:271-2. 10.1046\/j.1468-3083.2002.00485.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mjt.0000522273.81146.49","article-title":"Recurrent lower extremity pseudocellulitis","volume":"19","author":"Korniyenko A","year":"2012","unstructured":"Korniyenko A, Lozada J, Ranade A, Sandhu G. Recurrent lower extremity pseudocellulitis. Am J Ther. 2012, 19:e141-2. 10.1097\/01.mjt.0000522273.81146.49","journal-title":"Am J Ther"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2017.02.014","article-title":"Gemcitabine-associated acute lipodermatosclerosislike eruption: an underrecognized phenomenon","volume":"3","author":"Mittal A","year":"2017","unstructured":"Mittal A, Leventhal JS. Gemcitabine-associated acute lipodermatosclerosislike eruption: an underrecognized phenomenon. JAAD Case Rep. 2017, 3:190-5. 10.1016\/j.jdcr.2017.02.014","journal-title":"JAAD Case Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3747\/co.26.5007","article-title":"Gemcitabine-induced pseudocellulitis: a case report and review of the literature","volume":"26","author":"Bami H","year":"2019","unstructured":"Bami H, Goodman C, Boldt G, Vincent M. Gemcitabine-induced pseudocellulitis: a case report and review of the literature. Curr Oncol. 2019, 26:e703-6. 10.3747\/co.26.5007","journal-title":"Curr Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239-45. 10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/1078155214531610","article-title":"Recurrent pseudocellulitis due to gemcitabine: underrecognized and underreported?","volume":"21","author":"Dasanu CA","year":"2015","unstructured":"Dasanu CA, Bockorny B. Recurrent pseudocellulitis due to gemcitabine: underrecognized and underreported?. J Oncol Pharm Pract. 2015, 21:377-9. 10.1177\/1078155214531610","journal-title":"J Oncol Pharm Pract"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.52114","article-title":"Pemetrexed-Induced pseudocellulitis: a diagnostic conundrum","volume":"16","author":"Horton LA","year":"2024","unstructured":"Horton LA, Lyons AB, Kwa MC, Chaffins ML, Veenstra J. Pemetrexed-Induced pseudocellulitis: a diagnostic conundrum. Cureus. 2024, 16:e52114. 10.7759\/cureus.52114","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2006.06.021","article-title":"Unsuccessful rechallenge with pemetrexed after a previous radiation recall dermatitis","volume":"54","author":"Barl\u00e9si F","year":"2006","unstructured":"Barl\u00e9si F, Tummino C, Tasei AM, Astoul P. Unsuccessful rechallenge with pemetrexed after a previous radiation recall dermatitis. Lung Cancer. 2006, 54:423-5. 10.1016\/j.lungcan.2006.06.021","journal-title":"Lung Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2023.04.016","article-title":"Pseudocellulitis in oncology patients: a single institutional retrospective analysis investigating the clinical presentation, therapeutic response, and implications for cancer therapy","volume":"12","author":"Pach JJ","year":"2023","unstructured":"Pach JJ, Nelson C, Leventhal JS. Pseudocellulitis in oncology patients: a single institutional retrospective analysis investigating the clinical presentation, therapeutic response, and implications for cancer therapy. JAAD Int. 2023, 12:186-8. 10.1016\/j.jdin.2023.04.016","journal-title":"JAAD Int"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/54.2.162","article-title":"Gemcitabine: a cytidine analogue active against solid tumors","volume":"54","author":"Hui YF","year":"1997","unstructured":"Hui YF, Reitz J. Gemcitabine: a cytidine analogue active against solid tumors. Am J Health Syst Pharm. 1997, 54:162-70; quiz 197-8. 10.1093\/ajhp\/54.2.162","journal-title":"Am J Health Syst Pharm"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199803000-00001","article-title":"Gemcitabine\u2014a safety review","volume":"9","author":"Aapro MS","year":"1998","unstructured":"Aapro MS, Martin C, Hatty S. Gemcitabine\u2014a safety review. Anticancer Drugs. 1998, 9:191-201. 10.1097\/00001813-199803000-00001","journal-title":"Anticancer Drugs"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2015.04.007","article-title":"Gemcitabine-induced pseudocellulitis in a patient with non-small cell lung carcinoma","volume":"1","author":"Asemota E","year":"2015","unstructured":"Asemota E, Reid E, Kovarik C. Gemcitabine-induced pseudocellulitis in a patient with non-small cell lung carcinoma. JAAD Case Rep. 2015, 1:178-81. 10.1016\/j.jdcr.2015.04.007","journal-title":"JAAD Case Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X18809268","article-title":"Gemcitabine-induced skin necrosis","volume":"6","author":"Haydock MM","year":"2018","unstructured":"Haydock MM, Sigdel S, Pacioles T. Gemcitabine-induced skin necrosis. SAGE Open Med Case Rep. 2018, 6:2050313X18809268. 10.1177\/2050313X18809268","journal-title":"SAGE Open Med Case Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2011.01353.x","article-title":"Livedo reticularis as an initial clinical manifestation of gemcitabine-induced hemolytic uremic syndrome","volume":"39","author":"Zemtsov A","year":"2012","unstructured":"Zemtsov A, Omueti-Ayoade K, Zemtsov R, Yang M. Livedo reticularis as an initial clinical manifestation of gemcitabine-induced hemolytic uremic syndrome. J Dermatol. 2012, 39:487-9. 10.1111\/j.1346-8138.2011.01353.x","journal-title":"J Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/1078155216635852","article-title":"A rash diagnosis: gemcitabine-associated pseudocellulitis","volume":"23","author":"Strouse C","year":"2017","unstructured":"Strouse C, Epperla N. A rash diagnosis: gemcitabine-associated pseudocellulitis. J Oncol Pharm Pract. 2017, 23:157-60. 10.1177\/1078155216635852","journal-title":"J Oncol Pharm Pract"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200001000-00003","article-title":"Time- and dose-limiting erysipeloid rash confined to areas of lymphedema following treatment with gemcitabine--a report of three cases","volume":"11","author":"Brandes A","year":"2000","unstructured":"Brandes A, Reichmann U, Plasswilm L, Bamberg M. Time- and dose-limiting erysipeloid rash confined to areas of lymphedema following treatment with gemcitabine--a report of three cases. Anticancer Drugs. 2000, 11:15-7. 10.1097\/00001813-200001000-00003","journal-title":"Anticancer Drugs"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1086\/520684","article-title":"Gemcitabine-related \"pseudocellulitis\": report of 2 cases and review of the literature","volume":"45","author":"Tan DH","year":"2007","unstructured":"Tan DH, Bunce PE, Liles WC, Gold WL. Gemcitabine-related \"pseudocellulitis\": report of 2 cases and review of the literature. Clin Infect Dis. 2007, 45:e72-6. 10.1086\/520684","journal-title":"Clin Infect Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-012-2101-x","article-title":"Gemcitabine associated pseudocellulitis","volume":"27","author":"Singh A","year":"2012","unstructured":"Singh A, Hampole H. Gemcitabine associated pseudocellulitis. J Gen Intern Med. 2012, 27:1721. 10.1007\/s11606-012-2101-x","journal-title":"J Gen Intern Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2001.07.001","article-title":"Gemcitabine-associated scleroderma-like changes of the lower extremities","volume":"51","author":"Bessis D","year":"2004","unstructured":"Bessis D, Guillot B, Legouffe E, Guilhou JJ. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol. 2004, 51:S73-6. 10.1016\/j.jaad.2001.07.001","journal-title":"J Am Acad Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0b013e3182204ffe","article-title":"Gemcitabine-associated \"pseudocellulitis\" and \"pseudosepsis\": a case report and review of the literature","volume":"20","author":"Obeid KM","year":"2013","unstructured":"Obeid KM, Venugopal AA. Gemcitabine-associated \"pseudocellulitis\" and \"pseudosepsis\": a case report and review of the literature. Am J Ther. 2013, 20:118-20. 10.1097\/MJT.0b013e3182204ffe","journal-title":"Am J Ther"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.79a.11121","article-title":"Distinguishing cellulitis from its mimics","volume":"79","author":"Keller EC","year":"2012","unstructured":"Keller EC, Tomecki KJ, Alraies MC. Distinguishing cellulitis from its mimics. Cleve Clin J Med. 2012, 79:547-52. 10.3949\/ccjm.79a.11121","journal-title":"Cleve Clin J Med"},{"key":"ref22","article-title":"Alternative diagnoses that often mimic cellulitis","volume":"67","author":"Hepburn MJ","year":"2003","unstructured":"Hepburn MJ, Dooley DP, Ellis MW. Alternative diagnoses that often mimic cellulitis. Am Fam Physician. 2003, 67:2471.","journal-title":"Am Fam Physician"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2011.01398.x","article-title":"Cellulitis: diagnosis and management","volume":"24","author":"Bailey E","year":"2011","unstructured":"Bailey E, Kroshinsky D. Cellulitis: diagnosis and management. Dermatol Ther. 2011, 24:229-39. 10.1111\/j.1529-8019.2011.01398.x","journal-title":"Dermatol Ther"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1080\/08998280.2021.1974271","article-title":"Acute inflammatory edema as a variant of pseudocellulitis resolved after transcatheter aortic valve implantation","volume":"35","author":"Shalabi MM","year":"2022","unstructured":"Shalabi MM, Dacy NN, Grimwood RE, Fiala K, Amenell M. Acute inflammatory edema as a variant of pseudocellulitis resolved after transcatheter aortic valve implantation. Proc (Bayl Univ Med Cent). 2022, 35:91-2. 10.1080\/08998280.2021.1974271","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2021.1953982","article-title":"Clinical and immunologic differences in cellulitis vs. pseudocellulitis","volume":"17","author":"Goldenberg M","year":"2021","unstructured":"Goldenberg M, Wang H, Walker T, Kaffenberger BH. Clinical and immunologic differences in cellulitis vs. pseudocellulitis. Expert Rev Clin Immunol. 2021, 17:1003-13. 10.1080\/1744666X.2021.1953982","journal-title":"Expert Rev Clin Immunol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00659-8","article-title":"Cellulitis: a review of current practice guidelines and differentiation from pseudocellulitis","volume":"23","author":"Boettler MA","year":"2022","unstructured":"Boettler MA, Kaffenberger BH, Chung CG. Cellulitis: a review of current practice guidelines and differentiation from pseudocellulitis. Am J Clin Dermatol. 2022, 23:153-65. 10.1007\/s40257-021-00659-8","journal-title":"Am J Clin Dermatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.1735","article-title":"Chemotherapy-induced pseudocellulitis without prior radiation exposure: a systematic review","volume":"159","author":"Kovacs LD","year":"2023","unstructured":"Kovacs LD, O'Donoghue M, Cogen AL. Chemotherapy-induced pseudocellulitis without prior radiation exposure: a systematic review. JAMA Dermatol. 2023, 159:870-4. 10.1001\/jamadermatol.2023.1735","journal-title":"JAMA Dermatol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2016.3816","article-title":"Costs and consequences associated with misdiagnosed lower extremity cellulitis","volume":"153","author":"Weng QY","year":"2017","unstructured":"Weng QY, Raff AB, Cohen JM, et al.. Costs and consequences associated with misdiagnosed lower extremity cellulitis. JAMA Dermatol. 2017, 153:141-6. 10.1001\/jamadermatol.2016.3816","journal-title":"JAMA Dermatol"},{"key":"ref29","article-title":"The effect of implementing teledermatology in patients presenting with cellulitis versus pseudocellulitis in an academic emergency department setting: a pilot study","volume":"13","author":"Wells A","year":"2020","unstructured":"Wells A, Gupta P, Tian F, Adkins E, Kaffenberger B. The effect of implementing teledermatology in patients presenting with cellulitis versus pseudocellulitis in an academic emergency department setting: a pilot study. J Clin Aesthet Dermatol. 2020, 13:43-4.","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.6197","article-title":"Outcomes of early dermatology consultation for inpatients diagnosed with cellulitis","volume":"154","author":"Li DG","year":"2018","unstructured":"Li DG, Xia FD, Khosravi H, et al.. Outcomes of early dermatology consultation for inpatients diagnosed with cellulitis. JAMA Dermatol. 2018, 154:537-43. 10.1001\/jamadermatol.2017.6197","journal-title":"JAMA Dermatol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1177\/1078155217719584","article-title":"Gemcitabine associated pseudocellulitis: a missed diagnosis","volume":"24","author":"Gill D","year":"2018","unstructured":"Gill D, Schrader J, Kelly M, Martinez F, Syed W, Wright J. Gemcitabine associated pseudocellulitis: a missed diagnosis. J Oncol Pharm Pract. 2018, 24:550-2. 10.1177\/1078155217719584","journal-title":"J Oncol Pharm Pract"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/318683-pseudocellulitis-due-to-antineoplastic-therapy-a-case-of-atypical-presentation-and-recent-developments","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T19:31:39Z","timestamp":1748028699000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/318683-pseudocellulitis-due-to-antineoplastic-therapy-a-case-of-atypical-presentation-and-recent-developments"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":31,"URL":"https:\/\/doi.org\/10.7759\/cureus.84688","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,23]]}}}